Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label imaging study of sonelokimab in axial spondyloarthritis
2024-513498-36-00Phase 2Completed
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Nov 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonelokimab in axial spondyloarthritis (axSpA), sponsored by MoonLake Immunotherapeutics. Primary endpoint: Change from baseline in 18F-NaF SUVmax signals at Week 12 in the sacroiliac joints and spine. Started Nov 2024; status: completed.
02
Drugs
sonelokimab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2024-513498-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513498-36-00.